ReviewCNS drugs2025
Foslevodopa/Foscarbidopa: A Review in Advanced Parkinson's Disease.
Review in CNS drugs, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Do We Need to Monitor B-Vitamins and Homocysteine During Initiation of Foslevodopa/Foscarbidopa Therapy?Movement disorders : official journal of the Movement Disorder Society · 2026Article
- Is continuous dopaminergic delivery still a major goal to be achieved in the treatment of Parkinson's disease?Journal of Parkinson's disease · 2026Review
- Review
- Investigation of the In Vitro Neuroprotective Potential of Aegiceras corniculatum against MPTP-induced Toxicity.Applied biochemistry and biotechnology · 2026Article
- Article
- Outcome of People with Parkinson's Disease Treated with Levodopa-Entacapone-Carbidopa Intestinal Gel Who Failed Previous Subcutaneous Foslevodopa/Foscarbidopa.Brain sciences · 2026Article
- Sleep quality improvement after switching from levodopa/carbidopa intestinal gel to continuous subcutaneous foslevodopa/foscarbidopa infusion in advanced Parkinson's disease: a case report.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Foslevodopa/foscarbidopa [PRODUODOPA
Indexed as
Identifiers
40198538What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.